Clinical Trial of the Effects of DHA in the Treatment of Seizure Disorders
For many years, there has been interest in the question of whether a special diet of some sort could be used to help control epileptic seizures. The ketogenic diet has been used since the 1920s, but it is used only in children, and is nutritionally unbalanced. It is typically withdrawn after 3 years. The ketogenic diet unfortunately, offers no long-term solution to seizure control.
Our preliminary research now suggests that there may be a healthy, long-term dietary approach to controlling seizures.
Based on our animal work and published clinical studies the investigators hypothesize that a DHA dose of 3 g/day will reduce seizure frequency in patients with intractable seizures.
Epilepsy (Treatment Refractory)
Dietary Supplement: Fish Oil
Other: Safflower Oil
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Double Blind Placebo Controlled Trial of Anticonvulsant Effects of n-3 PUFAs in Human Subjects With Epilepsy|
- Seizure Diary [ Time Frame: 6 months ] [ Designated as safety issue: No ]The primary outcome measure of the study will be a measure of the number of seizures each month as recorded in a seizure diary - a record kept under the supervision of the study coordinator.
- Serum poly-unsaturated fatty acid levels [ Time Frame: 6 months ] [ Designated as safety issue: No ]Blood samples will be banked to allow for an assessment of change in blood levels of poly-unsaturated fatty acids between baseline and final study visit (6 months)
- Serum anticonvulsant levels [ Time Frame: 6 months ] [ Designated as safety issue: No ]Blood samples will be assessed for levels of anti-convulsant medications at baseline and 6 month time periods
- Adverse reactions [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]All adverse reactions incurred by all participants within the study will be collected, reported and assessed by type, intensity, severity, duration, and relationship to the study products
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||January 2017|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
Experimental: Fish Oil
Each capsule contains 625 mg of fish oil (100 mg EPA & 250 mg DHA). Participants will take 12 capsules per day over 6 months.
Dietary Supplement: Fish Oil
The daily dose is divided; capsules are taken with meals for a period of 6 months.
Placebo Comparator: Safflower Oil
Each capsule will contain 625 mg of Safflower oil. Participants will take 12 capsules per day over 6 months.
Other: Safflower Oil
Daily dose of safflower oil taken in divided doses as capsules and consumed with meals.
This will be a small, double-blind study involving placebo and 3 g/day of DHA. There will be a one-month baseline period, followed by a six month treatment period.
- Neurologists from the North York General Hospital or Toronto Western Hospital will refer patients being treated for intractable epilepsy.
- Patients will be contacted by phone by the study coordinator, who will explain the study and ask about willingness to participate. Inclusion and exclusion criteria will be discussed, as well as the patient's responsibilities. It will be made clear that there will be no cost to the patient.
- If patients are interested, a letter will be sent to them. The letter will contain a description of the study, the patient's responsibilities if he/she agrees to participate, and an explanation of informed consent.
One week after the letter, the study coordinator will again contact the patients by phone, answer any questions, and
- if the patient is willing to participate - set up the initial visit.
At the initial visit, the study coordinator will give the subject written and verbal information. Patients will be asked to sign an informed consent form. They will be given a seizure diary, to keep during the first month (prior to treatment) and to continue for the six months of treatment. The diary will record the frequency/type of seizures.
The study physician will review the medial history (seizure frequency/type), medications and blood work to be taken to measure serum levels of AEDs and n-3 PUFAs. About two teaspoons of extra blood will be taken and stored for possible future assays.
The study coordinator will then provide the patients with their appropriate capsules for the first three months of the trial. The rest will be mailed. The patient will receive written instructions on how to take the capsules. Only the study coordinator will know the patients' group assignments. (A sealed back-up of the code will be left with Dr. Burnham.) Patients will be given the study coordinator's cell phone number with instructions to call if they feel unwell at any time. If serious problems occur, the study coordinator will refer patients to the Emergency Department.
- Weekly telephone calls: Participants will receive scheduled weekly telephone calls from the study coordinator to collect any information recorded in the seizure diaries during the one month baseline period continuing through the sixth month treatment period.
- After the last month of the trial, a second in-person visit will be scheduled to re-examine the patient, and order more blood work. (Two teaspoons of the blood will be reserved for possible future assays.) At the end of the visit, The study coordinator will debrief the patient and give him/her a letter of thanks from the P.I. The patient will then be told where he/she can purchase DHA if he/she wants to continue.
- Data will be analyzed by Dr. Burnham. After data analysis, patients will be informed about the results of the whole by letter.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01769092
|North York General Hospital|
|Toronto, Ontario, Canada, M2K 1E1|
|Toronto Western Hospital|
|Toronto, Ontario, Canada|
|Principal Investigator:||Paul A Hwang, MD||North York General Hospital|
|Study Director:||Mac Burnham, PhD||University of Toronto Epilepsy Research Program (UTERP)|
|Principal Investigator:||Peter Carlen, MD||University Health Network, Toronto|